ASN95 -- Selected abstracts: Bone Disease, Vitamin D, PTH

Sun. Nov. 5 1995

9:30 A.M. ---Poster--- San Diego Conv Ctr Halls A and B
Parathyroid hormone/vitamin D I

Program number 16 Board# S16 at 10:45 A.M.
* Monoclonal proliferation of nodules in parathyroid hyperplasia due to chronic renal failure. Y. Tominaga, Y. Namii, T. Haba, K. Uchida, M. Numano, Y. Tanaka and H. Takagi. - Nagoya, Japan.

Program number 18 Board# S18 at 10:45 A.M.
* Expression of bcl-2 oncoprotein in parathyroid tissue of patients with primary and secondary hyperparathyroidism. J. Gogusev, P. duChambon, P. Zhang, M. Dousseau, M. Giovannini, E. Sarfati and T.B. Drueke. - Paris, France.

Program number 21 Board# S21 at 10:45 A.M.
* Lack of correlation between vitamin D receptor content and calcitriol-mediated gene transcription in resting and activated human macrophages. A. Dusso, S. Kamimura, M. Gallieni, L. Negrea and E. Slatopolsky. - St. Louis, Mo.

Program number 26 Board# S26 at 10:45 A.M.
* In vivo effects of intravenous 1,25-dihydroxyvitamin D3 on interleukin-2 production in hemodialysis patients. T. Rampino, C. Libetta, A. Dal Canton, W. DeSimone and B. Memoli. - Naples and Pavia, Italy.

Program number 31 Board# S31 at 10:45 A.M.
* Vitamin D3 receptor distribution in human parathyroid glands with secondary hyperparathyroidism. F. Caligara, F. Moatamed, J. Howanitz, A. Giangrande and F. Llach. - Busto Arsizio, Italy, Los Angeles, CA and Newark, NJ.

Program number 34 Board# S34 at 10:45 A.M.
* Marked expression of c-fos/jun proteins in hyperplastic parathyroid glands in CRF. T. Morishita, Y. Saitoh, Y. Tsukamoto and Y. Tominaga. - Kanagawa and Nagoya, Japan.

Program number 35 Board# S35 at 10:45 A.M.
* Dietary phosphate restriction downregulates renal vitamin D 24-hydroxylase mrna: Role of IGF-i and antagonism with 1,25-dihydroxyvitamin D3. A.J. Brown, S. Wu, J. Finch, C. Ritter and M. Grieff. -St. Louis, Mo.
9:30 A.M. ---Poster--- San Diego Conv Ctr Halls A and B
Clinical transplantation II

Program number 375 Board# S375 at 10:45 A.M.
* Nasal calcitonin reduces bone loss in renal transplant recipients. K.P. Nordal, J. Halse, J. Kronborg, E. Dahl and A.Hartmann. - Oslo, Norway.

Mon. Nov. 6 1995

9:00 A.M. ---Poster--- San Diego Conv Ctr Halls A and B
Parathyroid hormone/vitamin D II

Program number 822 Board# M91 at 10:00 A.M.
* Vitamin D receptor gene polymorphisms and severity of secondary hyperparathyroidism in CRF. Y. Tsukamoto, N. Kobayashi, Y. Nomura and M. Heisi. - Kitasato and Kanagawa, Japan.

Program number 826 Board# M95 at 10:00 A.M.
* Effect of aging on renal responsiveness to parathyroid hormone in healthy men. A.A. Portale, E.T. Lonergan and B.P. Halloran. - San Francisco, CA.

Program number 828 Board# M97 at 10:00 A.M.
* Non-suppressible parathyroid hormone secretion is related to parathyroid gland size in uremic secondary hyperparathyroidism. O.S. Indridason and L.D. Quarles. - Durham, NC.

Program number 829 Board# M98 at 10:00 A.M.
* Secondary hyperparathyroidism complicated by parathyromatosis. C. Stehman-Breen, N. Muirhead, D. Thorning and D. Sherrard.- Seattle, WA.

Program number 830 Board# M99 at 10:00 A.M.
* Calcium-regulated parathyroid hormone release in mild and advanced secondary hyperparathyroidism. W.G. Goodman, T. Belin, B. Gales, H. Juppner, G.V. Segre and I.B. Salusky. - Los Angeles, CA and Boston, MA.

9:00 A.M. ---Poster--- San Diego Conv Ctr Halls A and B
Complications and outcomes in end-stage renal disease I

Program number 856 Board# M125 at 10:00 A.M.
* Low-dose DFO treatment (5 mg/kg) in acutely aluminum-intoxicated hemodialysis patients using two drug administration schedules. P.C. D'Haese, J.D. Barata, C. Pires, L.V. Lamberts, J. Simoes and M.E. De Broe. - Edegem, Belgium; and Lisbao and Evora, Portugal.

Program number 858 Board# M127 at 10:00 A.M.
* Suppression of 2;dg hyperparathyroidism by 1-alpha(OH)-vitamin D;162 in hemodialysis patients. A.U. Tan, Jr., B.S. Levine, R.B. Mazess, D.M. Kyllo, J.C. Knutson, C.W. Bishop and J.W. Coburn. - Los Angeles, Ca and Madison, WI.

Program number 862 Board# M131 at 10:00 A.M.
* Aluminum in cerebrospinal fluid is not bound to transferrin. G.F. Van landeghem, P.C. D'Haese, L.V. Lamberts and M.E. De Broe. - Edegem, Belgium.

Program number 1377 at 5:00
* Beta2-microglobulin modified with advanced glycation endproducts enhances bone resorption of osteoclasts: Role in the pathogenesis of dialysis-related amyloidosis. T. Miyata, K. Notoyo, Y. Iida, S. Taketomi, M. Tsuda and K. Maeda.- Nagoya and Osaka, Japan.

4:00 P.M. ---Free Communications--- San Diego Conv Ctr Rm 11a
Parathyroid hormone/vitamin D

Program number 1412 at 4:15
* High phosphorus directly stimulates PTH secretion by human parathyroid tissue. Y. Almaden, A. Hernandez, V. Torregrosa, J. Campistol, A. Torres and M. Rodriguez. - Barcelona and Cordoba, Spain.

Program number 1413 at 4:30
* Phosphate (PO4) restriction prevents parathyroid cell growth in uremic rats and high phosphate directly stimulates PTH secretion in tissue culture. E. Slatopolsky, J. Finch, M. Denda, C. Ritter, M. Zhong, A. Dusso, P. MacDonald and A. Brown. - St. Louis, MO.

Program number 1415 at 5:00
* Induction of secondary hyperparathyroidism with recombinant human growth hormone in growth-stunted children with chronic renal diseases. C.B. Langman, D.E. Sailer, r.A. Cohn, S.R. Mendley, H.W. Schnaper, K.A. Schmeissing, L.T. Misiewicz and M. Marousek. - Chicago, IL.

Program number 1416 at 5:15
* Instantaneous control of spontaneous pulsatile PTH secretion by ionized serum calcium in healthy subjects. C.P. Schmitt, F. Schaefer, A. Bruch, H.J. Roth, E. Ritz and O. Mehls.- Heidelberg, Germany.

Tue. Nov. 7 1995

9:00 A.M. ---Poster--- San Diego Conv Ctr Halls A and B
Bone disease

Program number 1970 Board# T520 at 10:00 A.M.
* Role of the bone in the pathogenesis of idiopathic hypercalciuria: effect of aminobisphosphonate alendronate. E. Alonzo, D. Gil, E.Bellorin-Font, R. Carlini, V. Paz-martinez and J.R. Weisinger. - Caracas, Venezuela.

Program number 1972 Board# T522 at 10:00 A.M.
* Increased bone metabolism in chronic glomerulonephritis patients with mild decline in creatinine clearance. T. Fujino, T. Suzuki, T. Sato, T. Yasuda, T. Maeba, T. Komoda, S. Owada and M. Ishida. - Kawasaki and Saitama, Japan.

Program number 1973 Board# T523 at 10:00 A.M.
* Time course and functional correlates of post transplant aluminum elimination. P. Massari, G. Garay, S. Grosso, W. Douthat and J.Cannata. - Cordoba, Argentina and Oviedo, Spain.

Program number 1974 Board# T524 at 10:00 A.M.
* Decreased bone formation in idiopathic hypercalciuric calcium stone formers explains reduced bone density. P. Bataille, P. Hardy, A. Marie, I. Steiniche, M.E. Cohen-Solal, M. Brazier, A. Westeel and A. Fournier. - Amiens, France and Aarhus, Denmark.

Program number 1975 Board# T525 at 10:00 A.M.
* Increased strontium levels in bone of dialysis patients with osteomalacia. P.C. D'Haese, M-M. Couttenye, L.V. Lamberts, W.G. Goodman and M.E. De Broe. - Edegem, Belgium and Los Angeles, CA.

Program number 1977 Board# T527 at 10:00 A.M.
* Bone alkaline phosphatase in pediatric patients with chronic renal failure. D.E. Muller-Wiefel, B. Behnke, H. Altrogge and O. Amon.- Hamburg, Germany.

Program number 1978 Board# T528 at 10:00 A.M.
* Aluminum (Al) effects on endochrondral bone formation and mineralization in response to bone morphogenetic proteins depend on chemical form of and length of exposure to Al. J.M. Zhu, W.E. Huffer, P. Ruegg and A.C. Alfrey. -Denver, CO.

Program number 1980 Board# T530 at 10:00 A.M.
* Mild osteodystrophy: Is it really a mild disease? I. Mucsi, G. Hercz, W. Chan, D.J. Sherrard and Y. Pei. - Budapest, Hungary and Toronto, Canada.

Program number 1981 Board# T531 at 10:00 A.M.
* Calcium mass balance and its long-term effect on Ca-P metabolism and parathyroid function. O. Ortega, A. Oliet, P. Gallar, M.A. Bajo and A. Vigil. - Madrid, Spain.

Program number 1982 Board# T532 at 10:00 A.M.
* Aluminum transferrin but not Al citrate uptake by the parathyroid gland may contribute to the development of hypoparathyroidism associated with adynamic bone disease. K.A. Smans, P.C. D'Haese, G.F. Vanlandeghem, L.V. Lamberts and M.E. De Broe. - Edegem, Belgium.

Program number 1984 Board# T534 at 10:00 A.M.
* Bone mineral loss in chronic renal failure (CRF): A difference between young and old CRF patients. J. Cledes, R. Perrichot, J.P. Imiela and D. Baron. - Brest, France.

Wed. Nov. 8 1995


Program number 2163 at 11:30
* Serum parathyroid hormone levels as a predictor of the skeletal response to intermittent calcitriol therapy. I.B. Salusky, H. Juppner, G.V. Segre and W.G. Goodman. - Los Angeles, CA and Boston, MA.

Use BACK arrow on your browser (faster) or click here to go back to ASN95 main page

UP Click on ARROW for HDCN Home Page.